Lilly Sales Jump 39% on Zepbound and Mounjaro
Eli Lilly said Thursday that third-quarter revenue rose 39% to $24.4 billion, beating the $22.61 billion analysts expected (LSEG), as Mounjaro sales rose 65% to $10.72 billion and Zepbound rose 49% to $5.35 billion. Lilly raised its 2026 revenue forecast to $91–92 billion from $85–87 billion but trimmed its adjusted profit outlook to $35–36 a share because of deal charges. Sales of its new obesity pill, Foundayo, missed estimates.
What’s confirmed
- Eli Lilly said Thursday that third-quarter revenue rose 39% to $24.4 billion, beating the $22.61 billion analysts expected (LSEG), as Mounjaro sales rose 65% to $10.72 billion and Zepbound rose 49% to $5.35 billion.
- Lilly raised its 2026 revenue forecast to $91–92 billion from $85–87 billion but trimmed its adjusted profit outlook to $35–36 a share because of deal charges.
- Sales of its new obesity pill, Foundayo, missed estimates.
Confirmed by 4 independent outlets: CNBC, Reuters, MarketWatch and BioSpace.
What would move the score
- Now: 97% with 4 independent confirmations plus the primary source.
- Up: more independent outlets or primary records confirming the core claim.
- Down: a counted source correcting or walking back its report, or new evidence that weakens the claim.
Any change is logged below with the time and the old and new score. Corrections policy
Confirmation record
Plus the primary source: Lilly’s Q3 2026 earnings release.Updated / Corrected log
- Published at 97% with 4 independent confirmations.
Card video
TruthRank card · narrated, captions availableAny correction is logged here with its time and the reason. See our corrections policy.
TruthRank Daily
The day’s most-confirmed stories and their scores, in one short email.
Launching soon. Nothing is sent yet: before the first issue we’ll email you once to confirm. We use your address only for TruthRank Daily, never sell it, and you can unsubscribe any time. Privacy